Rekombinanter IL2RA (Basiliximab Biosimilar) Antikörper

Produktnummer ABIN5668050

Dieses Human Chimeric-Antikörper erkennt spezifisch IL2RA (Basiliximab Biosimilar) in FACS, BR, IF, IHC und WB. Er zeigt eine Reaktivität gegenüber Human, Cynomolgus und Rhesusaffen.

Kurzübersicht für Rekombinanter IL2RA (Basiliximab Biosimilar) Antikörper (ABIN5668050)

Target: IL2RA (Basiliximab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human, Cynomolgus, Rhesusaffen

Wirt: Human

Klonalität: Chimeric

Konjugat: Dieser IL2RA (Basiliximab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Blocking Reagent (BR), Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB)

Produktdetails anti-IL2RA (Basiliximab Biosimilar) Antikörper

Verwendungszweck: Anti-IL-2R alpha (CD25) [Basiliximab], Human IgG1, kappa

Spezifität: Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit - binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc) - T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.

Kreuzreaktivität: Cynomolgus, Rhesusaffen

Produktmerkmale:

Original Species of Ab: Human

Original Format of Ab: IgG1

Aufreinigung: Protein A affinity purified

Reinheit: > 98 % as determined by SDS-PAGE

Endotoxin-Niveau: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1κ constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.

Kommentare:

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu IL2RA (Basiliximab Biosimilar)

Target: IL2RA (Basiliximab Biosimilar)

Hintergrund: Interleukin-2 receptor subunit alpha, IL-2 receptor subunit alpha, IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD25.

UniProt: P01589